FDA-NDA208969
Document details
Summary
REXTOVY (naloxone hydrochloride), a nasal spray, will likely fall under Medicare Part D for oral drugs, as it is not injectable and thus not eligible for Part B billing. Billing teams should considerNew naloxone spray REXTOVY approved; watch for Part D billing.
Affected specialty
Infectious Disease alerts →Source document
http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/208969s000lbl.pdfCLV Intelligence summarizes publicly available federal publications. Not affiliated with or endorsed by any government agency.
Related alerts
4Policy FDA-NDA050817 · Infectious Disease
Baxter Healthcare's new dosage form of cefepime (injectable, NDA050817) follows the Part B billing pathway, consistent with its intravenous/injection route of administration typically administered in
View alertPolicy FDA-NDA218275 · Infectious Disease
Zevtera (ceftobiprole medocaril sodium) is an intravenous antibiotic approved via NDA218275, administered as a reconstituted powder for IV infusion, placing it squarely in the Medicare Part B billing
View alertPolicy LCD-L39044 · Clinical Laboratory
The LCD L39044 focuses on coverage for molecular syndromic panels for infectious disease pathogen identification. As a final LCD, it is currently active and will be effective starting June 25, 2026, i
View alertPolicy FDA-NDA021132 · Infectious Disease
Linezolid for suspension is an oral medication that will be billed under Medicare Part D. Since it does not have an injectable form, there will be no assignment of J-codes. Billing teams should monito
View alert